1428787-49-8

Basic information

• Product Name: (E)-N⁴-(3-fluoro-4-(6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinoline-4-yloxy)phenyl)-N¹-(benzylidene)semicarbazide
• Synonyms: (E)-N⁴-(3-fluoro-4-(6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinoline-4-yloxy)phenyl)-N¹-(benzylidene)semicarbazide
• CAS NO: 1428787-49-8
• Molecular Weight: 573.624
• Mol File: 1428787-49-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (E)-N⁴-(3-fluoro-4-(6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinoline-4-yloxy)phenyl)-N¹-(benzylidene)semicarbazide(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-N⁴-(3-fluoro-4-(6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinoline-4-yloxy)phenyl)-N¹-(benzylidene)semicarbazide(1428787-49-8)
• EPA Substance Registry System: (E)-N⁴-(3-fluoro-4-(6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinoline-4-yloxy)phenyl)-N¹-(benzylidene)semicarbazide(1428787-49-8)

Safety Data

• Hazardous Substances Data: 1428787-49-8(Hazardous Substances Data)

Upstream product

• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 
• 1449763-30-7 phenyl 3-fluoro-4-(6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yloxy)phenylcarbamate 
• 479690-10-3 3-Fluoro-4-{[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy}-aniline 
• 960299-44-9 4-(3-((4-(2-fluoro-4-nitrophenoxy)-6-methoxyquinolin-7-yl)oxy)propyl)morpholine 
• 205448-32-4 4-chloro-6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinoline 
• 1167053-13-5 6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-ol, sodium salt 
• 1394166-09-6 6-methyloxy-7-(4-(3-chloropropoxy))-4-4-hydroxyquinoline 
• 1449763-02-3 1-(4-(3-chloropropoxy)-5-methoxy-2-nitrophenyl)-3-(dimethylamino)propyl-2-en-1-one 
• 1449763-33-0 N¹-(3-fluoro-4-(6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yloxy)phenyl)semicarbazide 
• 100-52-7 benzaldehyde 
• 1160707-44-7 1-[4-(3-chloropropoxy)-5-methoxy-2-nitrophenyl]ethan-1-one 
• 58113-30-7 4-(3-chloropropoxy)-3-methoxyacetophenone 

Relevant articles and documents

NOVEL QUINOLINE DERIVATIVES AND THEIR APPLICATIONS

The invention relates to a series of quinoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs. Thereof M, R1, R2, X, Y and n are defined as claims. And the compounds of general formula I show potent inhibitory activity against c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically acceptable salts and hydrates for the preparation of medicaments for the treatment and/or prevention of diseases caused by abnormal expression of c-Met kinase, especially for treatment and/or prevention of cancer.